Any glass that's half full is also, equally, half empty. In...

Any glass that's half full is also, equally, half empty.

In other words, we need the Q2 earnings report to have any sense of verifiable progress and, equally, the progress that still needs to be made.

Even guessing possible revenue from raw sales (as great as they are) just won't get anywhere near the real and significant financials. The overheads are, as we all know, extremely complex in biotech.

The market out there knows this already. Add to this the understandable wariness of SPL based on historical track record. So, like other holders, I'm excited by the quick sales of Viraleze, but the bottom line for Q2 will need to be really solid to win market confidence, with ensuing improvement in SP. Even then, the real fillip may not come until an actual dividend is paid.

Only real money in the hand will make the glass more full and less empty.

I'm not trying to poop on anyone's party - just trying hard to keep my eyes wide open.